Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Jurnal MedScientiae Jurnal MedScientiae
Nicolas Layanto
Departemen Mikrobiologi Klinik, Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Kristen Krida Wacana, Jakarta, Indonesia
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Nursing Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Efektivitas Ceftazidime-Avibactam terhadap Bakteri Gram Negatif Penghasil Enzim Karbapenemase Ade Dharmawan; Nicolas Layanto
Jurnal MedScientiae Volume 1 No 01 : Mei - Agustus 2022
Publisher : Fakultas Kedokteran dan Ilmu Kesehatan Ukrida

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (372.965 KB) | DOI: 10.36452/jmedscientiae.vi.2453

Abstract

Antibiotic therapy is a major concern in the health sector. There is an increase in the resistance of gram-negative bacteria that produce carbapenemase enzymes to certain antibiotics, especially the β-lactam group, thus creating a new challenge for the health world to find stronger antibiotics to fight the resistance of these gram-negative bacteria. Currently, there are several new antibiotics that have been approved as treatment options, such as Ceftazidime-Avibactam. It is hoped that this new treatment can be an option, especially for gram-negative bacteria that produce carbapenemase enzymes.  
Efektivitas Ceftazidime-Avibactam terhadap Bakteri Gram Negatif Penghasil Enzim Karbapenemase Ade Dharmawan; Nicolas Layanto
Jurnal MedScientiae Vol. 1 No. 1 (2022): August
Publisher : Fakultas Kedokteran dan Ilmu Kesehatan Ukrida

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36452/jmedscie.v1i1.2453

Abstract

Antibiotic therapy is a major concern in the health sector. There is an increase in the resistance of gram-negative bacteria that produce carbapenemase enzymes to certain antibiotics, especially the β-lactam group, thus creating a new challenge for the health world to find stronger antibiotics to fight the resistance of these gram-negative bacteria. Currently, there are several new antibiotics that have been approved as treatment options, such as Ceftazidime-Avibactam. It is hoped that this new treatment can be an option, especially for gram-negative bacteria that produce carbapenemase enzymes.  
Co-Authors Ade Dharmawan